Mesoblast Limited (MESO)
NASDAQ: MESO · Real-Time Price · USD
13.18
+0.79 (6.38%)
At close: Oct 27, 2026, 4:00 PM EDT
13.44
+0.26 (1.97%)
After-hours: Oct 27, 2026, 7:59 PM EDT
Mesoblast Employees
Mesoblast had 108 employees as of June 30, 2026. The number of employees increased by 27 or 33.33% compared to the previous year.
Employees
108
Change (1Y)
27
Growth (1Y)
33.33%
Revenue / Employee
$1,113,426
Profits / Employee
-$532,407
Market Cap
1.69B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Jun 30, 2026 | 108 | 27 | 33.33% |
| Jun 30, 2025 | 81 | 8 | 10.96% |
| Jun 30, 2024 | 73 | -10 | -12.05% |
| Jun 30, 2023 | 83 | 6 | 7.79% |
| Jun 30, 2022 | 77 | -6 | -7.23% |
| Jun 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Ultragenyx Pharmaceutical | 1,371 |
| Immunocore Holdings | 524 |
| Intellia Therapeutics | 377 |
| Nuvation Bio | 305 |
| UroGen Pharma | 300 |
| Stoke Therapeutics | 170 |
| Absci | 140 |
MESO News
- 13 days ago - Mesoblast Ltd (MESO) Reports Fiscal Year Results with Mixed Signals on Growth and Valuation - GuruFocus
- 4 weeks ago - Mesoblast receives FDA approval for potency assay to release Ryoncil product - TheFly
- 4 weeks ago - Mesoblast Receives FDA Approval for New Potency Assay to Release Commercial Ryoncil Product - GlobeNewsWire
- 2 months ago - Mesoblast price target raised to $39 from $35 at Piper Sandler - TheFly
- 2 months ago - Full Year 2026 Mesoblast Limited Earnings Presentation Transcript - GuruFocus
- 2 months ago - Mesoblast Reports Substantial Revenue Growth to US$120M - GlobeNewsWire
- 2 months ago - Mesoblast H2 Earnings Call Highlights - MarketBeat
- 2 months ago - Mesoblast Earnings Call Transcript: H2 2026 - Transcripts